Avet-Loiseau, Hervé <br/><br/>
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.  [electronic resource] 

 -  Blood  09 2016 
 - 1174-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2016-03-707596  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oligopeptides--administration & dosage<br/>Recurrence<br/>Risk Factors<br/>Survival Rate<br/>Thalidomide--administration & dosage